 | |
- close
- close
|
FiercePharma
Nov 19
Comment
A federal appeals court has ruled that Cell Therapeutics can pursue a claim for nearly $23 million against a former consultant that advised it to market a drug off-label, adding a whole new wrinkle to whistleblower lawsuits. Report
TheStreet.com
Nov 16
Comment
'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.
Stock Blog Hub
Nov 15
Comment
Cell Therapeutics’ (CTIC) third quarter loss per share came in at 8 cents compared to a loss of $1.14 reported in the year ago period. The company does not have any marketed product at present; it derives revenues primarily in the form of...
StreetInsider.com
Oct 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Cell+Therapeutics+%28CTIC%29+Said+OPAXIO+Produces+High+Rates+of+Pathologic+Complete+Remission+in+Patients+with+Advanced+Esophageal+Cancer/4983249.html for the full story.
StreetInsider.com
Sep 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cell+Therapeutics+%28CTIC%29+Applies+for+European+Orphan+Drug+Designation+for+Pixantrone+in+Aggressive+Non-Hodgkin%27s+Lymphoma+%28NHL%29/4976089.html for the full story.
MarketWatch
Sep 29
Comment
Cell Therapeutics Inc., the Seattle biopharmaceutical company focused on cancer, said it filed with the European Medicines Agency for orphan-drug status for pixantrone, a treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma. The...
FierceBiotech
Sep 24
Comment
Cell Therapeutics has withdrawn its European application to market lung cancer drug Opaxio. In announcing the setback earlier this week, the company cited the concerns of an EMEA committee regarding its trial design. CTI had expected to...
TheStreet.com
Sep 22
Comment
Cell Therapeutics has withdrawn its European approval application for the lung cancer drug Opaxio. But you wouldn't quite get that from the company's statement Monday.
Stock Blog Hub
Sep 18
Comment
Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone for the treatment of patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).
The original...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
CTIC AT A GLANCE
Cell Therapeutics, Inc. is a biopharmaceutical company focused primarily on the development and commercialization of drugs fighting against various forms of cancer. It is involved in the development of several new drugs and has currently no marketed product since it sold in 2009 its 50% stake in the joint venture company with Spectrum Pharmaceuticals (SPPI).
In 2009 CTIC had two products ready for market release. One is going through FDA's evaluation through a New Drug Application (NDA) while the other has been filed for a Marketing Authorization Application (MAA) in the European Union.
References
| ||||||
|
|
